Results 51 to 60 of about 4,014 (178)
VirusesBackground: The advent of direct-acting antivirals (DAAs) has marked a significant milestone in the therapeutic landscape of hepatitis C, greatly improving treatment efficacy.
Jae Hyun Yoon +8 more
doaj +1 more source
Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C
International Journal of General Medicine, 2021 Lu-Hua Gao, Qing-He Nie, Xi-Tai Zhao Center of Infectious Diseases, Second Affiliated Hospital, Air-Force Military Medical University, Xi’an 710038, People’s Republic of ChinaCorrespondence: Qing-He NieCenter of Infectious Diseases, Second ...
Gao LH, Nie QH, Zhao XT
doaj
F1000Research, 2020 We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CLpro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and
Yu Wai Chen +2 more
doaj +1 more source
BMC Gastroenterology, 2020 Background We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6.
Phunchai Charatcharoenwitthaya +14 more
doaj +1 more source
Sofosbuvir-velpatasvir en pacientes mexicanos con hepatitis C: una revisión retrospectiva
Revista de Gastroenterología de México, 2022 Resumen: Introducción: La combinación de sofosbuvir-velpatasvir (SOF/VEL) es una terapia antiviral de acción directa que está autorizada y disponible en México.
J.L. Pérez-Hernández +16 more
doaj +1 more source
Development of a Machine Learning Model to Predict Short Duration HCV Treatment Response
Journal of Viral Hepatitis, Volume 33, Issue 10, October 2026.ABSTRACT Standard durations of direct acting antivirals (DAAs; 8–12 weeks) can be a barrier to HCV treatment initiation and completion among marginalized populations. This study developed and internally validated a machine learning model to predict short‐duration (4–6 weeks) DAA response using baseline clinical factors with potential to improve ...
Joanne M. Carson +7 more
wiley +1 more source
Perspectives in Clinical Research, 2021 Context: The Indian government is dispensing newer direct-acting antiviral (DAA) drugs, which may have impact on hepatitis C virus (HCV) patients’ quality of life (QoL).
Bhavya H Vyas +4 more
doaj +1 more source
Liver International, Volume 46, Issue 10, October 2026.ABSTRACT Background and Aims Ensuring access to direct‐acting antivirals (DAA) for all individuals concerned is a priority in hepatitis C elimination efforts. We analysed sex disparities in DAA initiation in France over a 9‐year period spanning before and after August 2017, when the country implemented universal DAA access.
Fabienne Marcellin +12 more
wiley +1 more source
Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C
, 2017 Objectives: To review the pharmacology, efficacy, and safety of sofosbuvir/velpatasvir in the treatment of patients with hepatitis C virus (HCV) infection.
Hemstreet, Brian +5 more
core +1 more source
Prenatal testing and postpartum treatment for hepatitis C virus among women with opioid use disorder
Pregnancy, Volume 2, Issue 5, September 2026.Abstract Introduction In the past decade, hepatitis C virus (HCV) infections among pregnant women increased dramatically in the United States, rising in parallel with the opioid crisis and increasing the number of children at risk for HCV. People with HCV infection that remains untreated are also at increased risk of cirrhosis, liver cancer, and death.
Lucas Gosdin +19 more
wiley +1 more source